Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.5%. By the end of trading, Bristol-Myers Squibb Company fell $0.86 (-1.6%) to $53.95 on heavy volume. Throughout the day, 14,045,762 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7,699,100 shares. The stock ranged in price between $52.71-$54.31 after having opened the day at $54.31 as compared to the previous trading day's close of $54.81. Other companies within the Drugs industry that declined today were: Cleveland BioLabs ( CBLI), down 33.6%, Emergent BioSolutions Incorporated ( EBS), down 10.8%, Herbalife ( HLF), down 10.3% and Acceleron Pharma ( XLRN), down 10.0%.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $89.9 billion and is part of the health care sector. The company has a P/E ratio of 32.9, above the S&P 500 P/E ratio of 17.7. Shares are up 3.1% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Hemispherx Biopharma ( HEB), up 19.6%, CEL-SCI Corporation ( CVM), up 12.6%, Ariad Pharmaceuticals ( ARIA), up 12.1% and Bacterin International Holdings ( BONE), up 8.8% , were all gainers within the drugs industry with Novartis ( NVS) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact